
Janssen Korea’s Zytiga secures expanded reimbursement for 1st-line prostate cancer treatment
Beginning in April, Janssen Korea's prostate cancer drug Zytiga will be available with prednisolone as a first-line treatment for patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC), with the patient …